-
Fosun Pharma Inks Licensing Deal with Neovii for GvHD Therapy Grafalon
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) signed an exclusive licensing agreement with Swiss firm Neovii Pharmaceuticals AG, focusing on Neovii’s graft versus host disease (GvHD) therapy Grafalon (rabbit anti-human T-lymphocyte globulin, ATLG). Under the deal, Fosun gains development and commercialization rights to Grafalon in Greater…
-
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
•
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I clinical trial filing for its topical JAK1 selective inhibitor FZJ-003 gel (specification: 1%, 2%) in atopic dermatitis (AD) has been accepted for review. Global JAK Inhibitor MarketGlobally, nine JAK inhibitors are currently marketed, including Sanofi/Incyte’s…
-
HutchMed’s Elunate Shows Survival Benefit in Global CRC Study at ESMO
•
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the results of the pivotal global Phase III FRESCO-2 study for its VEGFR 1/2/3 inhibitor Elunate (fruquintinib) in advanced refractory metastatic colorectal cancer (CRC) at the European Society for Medical Oncology (ESMO) 2022 annual meeting. Study Design and ResultsThe multi-center…
-
Jacobio’s KRAS G12C Inhibitor JAB-21822 Advances to Pivotal Phase II in NSCLC
•
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has received approval from the National Medical Products Administration (NMPA) to launch a pivotal Phase II trial of its KRAS G12C inhibitor, JAB-21822, for advanced or metastatic non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. The company plans to file…
-
Lianren Digital Health Partners with Ningbo Government on Health Data Ecosystem
•
Shanghai-based Lianren Digital Health has forged a strategic partnership with the People’s Government of Ningbo Municipality, announced at the World Digital Economy Conference 2022. The collaboration aims to enhance Ningbo’s healthcare digital infrastructure and data utilization, with no financial terms disclosed.Partnership Goals The alliance will focus on three pillars:Upgrading health…
-
Bio-Heart Invests RMB 50M in Cardiotek to Advance Balloon-Expandable TAVR Device
•
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese interventional cardiovascular device maker, will invest RMB 50 million (USD 7.2 million) in compatriot firm Cardiotek HK Ltd, securing a 9.09% stake. The deal underscores Bio-Heart’s expansion into transcatheter aortic valve replacement (TAVR) technology, complementing its core bioresorbable scaffold…
-
HitGen’s Vernalis Subsidiary Collaborates with Unison Medicines on Undruggable Bacterial Target
•
China’s HitGen Inc. (SHA: 688222) announced a strategic research collaboration between its wholly owned subsidiary, Vernalis Research, and U.S.-based Unison Medicines Inc., targeting an undisclosed bacterial pathogen previously deemed “undruggable.” The partnership leverages Vernalis’ drug discovery expertise to design small-molecule therapies, with Unison funding all R&D activities and sharing downstream…
-
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Shows Superior Booster Efficacy in Phase III Trial
•
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) reported positive Phase III trial results for its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a universal booster shot. The study demonstrated superior neutralizing antibody responses against the wild strain and Omicron subvariants BA.1/BA.2 compared to homologous inactivated vaccine boosters. Trial Design and ResultsThe…
